The U.S. surpassed 500,000 deaths Monday, marking the latest grim milestone in the country's battle against the COVID-19 pandemic.

Health experts anticipated reaching the current death toll this month, as cases and hospitalizations peaked last month. Even as the trend is decreasing on both fronts, with deaths likely to slow in coming weeks, variants circulating bring a new wave of concerns.

President Joe Biden held a vigil Monday evening to remember the 500,000 lives lost.

Read more: joker

"While we have been fighting this pandemic for so long, we have to resist becoming numb to the sorrow. We have to resist viewing each life as a statistic or a blur or on the news. And we must do so to honor the dead, but equally important, care for the living and those left behind," Biden said.

Projections of the circulation of the U.K. variant (B.1.1.7) show it will be the dominant strain in the U.S. by March. Studies are ongoing about the effects of the new strain, with the U.K. saying earlier this month it could be more deadly in addition to being more transmissible. But health experts believe the vaccines will continue to be effective in protecting against the strain.

Meanwhile, Johnson & Johnson (JNJ) is slated to have its vaccine candidate analyzed by independent experts for the U.S. Food and Drug Administration (FDA), with anticipation of a rollout coming as early as the weekend. The single-dose vaccine would alleviate the burden on administrators for current two-dose vaccines and could help to reach more vulnerable populations because it requires less-intense cold storage than mRNA vaccines.

Novavax (NVAX), another vaccine candidate that has commitments for its candidate in the U.S. and globally, is now fully enrolled for its Phase 3 clinical trial, with results and a filing for emergency use authorization expected by Spring.

Another candidate from GlaxoSmithKline (GSK) and Sanofi (SNY), which partnered for the effort, is moving ahead with a new formulation for Phase 2 after a previous version was deemed ineffective. The duo expects to start Phase 3 by the second quarter if all goes well.